Bausch & Lomb

Gary Nachman of BMO Capital Markets has some good news and bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s investors following the company's third-quarter earnings report. The good news is that Valeant's new segment reporting could provide greater visibility on its business outlook. The...

Things seem to keep getting worse and worse for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its shareholders, including last week’s deep guidance cut. Barclays analyst Douglas Tsao believes Valeant’s new management team is taking steps in the right direction, but the journey will...

Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...

U.S. stocks were mixed as the Dow finished in positive territory and the S&P 500 index turned negative after rising to within two points of its record close. The Nasdaq also turned negative towards the end of the day, declining for the third straight day. Earnings continue to come in mixed...

It’s a sign of the times in health care. If you can’t generate growth, buy it. The New York Times sounded that familiar theme in reporting the pending acquisition Monday of Rochester, N ew York-based Bausch & Lomb by Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX). J. Michael...